RS-1047

RS-1047 is an investigational radiopharmaceutical developed by RS Research (RS Araştırma Eğitim Danışmanlık İlaç Sanayi Ticaret) for oncological applications. It is designed as a radioligand for both diagnostic imaging and targeted radionuclide therapy (theranostics). While the specific molecular target of RS-1047 has not been publicly disclosed, it is part of a pipeline that leverages the company's expertise in targeted delivery. The asset is intended to selectively bind to tumor-associated antigens, allowing for the localized delivery of radiation to cancer cells while minimizing damage to healthy tissue. RS Research typically utilizes its proprietary Sagitta platform, a biodegradable polymer-based delivery system, to enhance the targeting and safety profile of its drug candidates.